R. Daniel Meyer
Pfizer (United States) · 30 works · 1,599 citations · h-index 15
Top works
- An Analysis for Unreplicated Fractional Factorials
- Dispersion Effects from Fractional Designs
- Dispersion Effects From Fractional Designs
- Finding the Active Factors in Fractionated Screening Experiments
- Follow-Up Designs to Resolve Confounding in Multifactor Experiments
- Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic
- Some new ideas in the analysis of screening designs
- Optimizing Higher Throughput Methods to Assess Drug–Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50
- Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences
- All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials
- Visualization of data
- Bayesian variable assessment
- Analysis of unreplicated factorials allowing for possibly faulty observations
- HIV prevention trial design in an era of effective pre-exposure prophylaxis
- Studies in Quality Improvement II. An Analysis for Unreplicated Fractional Factorials
- Variable Selection or Variable Assessment
- Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials
- Analysis of Factorial Experiments.
- Studies in Quality Improvement. I. Dispersion Effects from Fractional Designs. Revised
- George Box and Bayesian inference